A role for glycolipid biosynthesis in severe fever with thrombocytopenia syndrome virus entry
Open Access
- 7 April 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (4) , e1006316
Abstract
A novel bunyavirus was recently found to cause severe febrile illness with high mortality in agricultural regions of China, Japan, and South Korea. This virus, named severe fever with thrombocytopenia syndrome virus (SFTSV), represents a new group within the Phlebovirus genus of the Bunyaviridae. Little is known about the viral entry requirements beyond showing dependence on dynamin and endosomal acidification. A haploid forward genetic screen was performed to identify host cell requirements for SFTSV entry. The screen identified dependence on glucosylceramide synthase (ugcg), the enzyme responsible for initiating de novo glycosphingolipid biosynthesis. Genetic and pharmacological approaches confirmed that UGCG expression and enzymatic activity were required for efficient SFTSV entry. Furthermore, inhibition of UGCG affected a post-internalization stage of SFTSV entry, leading to the accumulation of virus particles in enlarged cytoplasmic structures, suggesting impaired trafficking and/or fusion of viral and host membranes. These findings specify a role for glucosylceramide in SFTSV entry and provide a novel target for antiviral therapies. As obligate, intracellular parasites, viruses depend upon numerous host-derived factors to replicate. For many bunyaviruses, these pro-viral host factors are largely uncharacterized. In the present study, we used an unbiased genetic screening strategy to identify human genes that facilitate the entry process of a newly discovered pathogenic bunyavirus, severe fever with thrombocytopenia syndrome virus (SFTSV). Our screen and subsequent validation confirmed a role for the glucose-modified lipid, glucosylceramide (GlcCer), in the entry of SFTSV. We found that depletion of GlcCer in the cell leads to the accumulation of virus particles in membranous compartments, suggesting that the virions cannot properly access the cytoplasm to initiate replication. Clinically available compounds that target GlcCer formation may provide a novel antiviral therapeutic strategy for this newly emerged virus.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (T32AI007324-23)
- National Institute of General Medical Sciences (T32GM007229-37)
- Wellcome Trust (099220/Z/12/Z)
- U.S. Department of War (W81XWH-14-1-0204)
- National Institute of Allergy and Infectious Diseases (AI 052845)
- National Institute of Allergy and Infectious Diseases (AI 082020)
This publication has 58 references indexed in Scilit:
- Suppression of the Interferon and NF-κB Responses by Severe Fever with Thrombocytopenia Syndrome VirusJournal of Virology, 2012
- Orthobunyavirus Entry into Neurons and Other Mammalian Cells Occurs via Clathrin-Mediated Endocytosis and Requires Trafficking into Early EndosomesJournal of Virology, 2012
- The Ecology, Genetic Diversity, and Phylogeny of Huaiyangshan Virus in ChinaJournal of Virology, 2012
- Acute Thrombocytopenia, Leucopenia, and Multiorgan Dysfunction: The First Case of SFTS Bunyavirus outside China?Case Reports in Infectious Diseases, 2011
- Ebola virus entry requires the cholesterol transporter Niemann–Pick C1Nature, 2011
- Global gene disruption in human cells to assign genes to phenotypes by deep sequencingNature Biotechnology, 2011
- Fever with Thrombocytopenia Associated with a Novel Bunyavirus in ChinaNew England Journal of Medicine, 2011
- Insights into bunyavirus architecture from electron cryotomography of Uukuniemi virusProceedings of the National Academy of Sciences, 2008
- HIV integration site selection: Analysis by massively parallel pyrosequencing reveals association with epigenetic modificationsGenome Research, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001